Nadofaragene Firadenovec

Phase 3Gene therapy

Ferring

Nadofaragene Firadenovec is one of 47 small molecule programs targeting Bladder Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder CancerActive, not recruiting

Non Muscle Invasive Bladder CancerRecruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in SituRecruiting

Bladder CancerPhase 3

Active, not recruiting

Non Muscle Invasive Bladder CancerPhase 3

Recruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in SituPhase 3

Recruiting

Competition

Competitive Landscape

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

57 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

61 3

Velban

Eli Lilly

Phase 3

8 4

Adriamycin

Pfizer

Phase 3

6 5

Javlor

Bristol-Myers Squibb

Phase 3

5 6

Taxotere

AAvyxa

Phase 3

11 7

Paraplatin

AAvyxa

Phase 3

9 8

Aquasol E

NNational Eye Institute (NEI)

Phase 3

2 9

Mitomycin C

GGynecologic Oncology Group

Phase 3

16 10

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Bladder Cancer

NCT07332351

Q2 2028

Phase 3Recruiting

Bladder Cancer

NCT06929286

Q4 2029

Phase 1/2Recruiting

UTUC

NCT06668493

Q4 2030

Phase 3Recruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06545955

Clinical

Trials by Indication[1]

Bladder Cancer2 trials

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Not yet recruiting·UUniversity of Washington·Phase 2·NCT07332351·33 enrolled

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT06929286·125 enrolled

Complete Response1 trial

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Withdrawn· Ferring logo

Ferring·Phase 4·NCT06390111

UTUC1 trial

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Recruiting· Ferring logo

Ferring·Phase 1/2·NCT06668493·20 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting· Ferring logo

Ferring·Phase 3·NCT06510374·454 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1 trial

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Ferring logo

Ferring·Phase 3·NCT06545955·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Nadofaragene Firadenovec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nadofaragene Firadenovec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nadofaragene Firadenovec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: Ferring

Nadofaragene Firadenovec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q4 2029

Q4 2030

Trials by Indication[1]

Bladder Cancer2 trials

Complete Response1 trial

UTUC1 trial

Non Muscle Invasive Bladder Cancer1 trial

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1 trial

References

Drug Info

Quick Facts

Related News